Deep‐learning model to improve histological grading and predict upstaging of atypical ductal hyperplasia / ductal carcinoma in situ on breast biopsy

CY Huang, RF Chang, CY Lin, MS Hsieh… - …, 2024 - Wiley Online Library
Aims Risk stratification of atypical ductal hyperplasia (ADH) and ductal carcinoma in situ
(DCIS), diagnosed using breast biopsy, has great clinical significance. Clinical trials are …

Abstract P5-02-02: Artificial intelligence powered predictive analysis of atypical ductal hyperplasia from digitized pathology images

JK Kerner, A Cleary, S Jain, H Pokkalla, B Glass… - Cancer Research, 2020 - AACR
Abstract Background: Approximately 15-25% of patients with atypical ductal hyperplasia
(ADH) diagnosed on breast core needle biopsy (CNB) are upgraded to ductal carcinoma in …

Improving classification with forced labeling of other related classes: application to prediction of upstaged ductal carcinoma in situ using mammographic features

R Hou, B Shi, LJ Grimm… - Medical Imaging …, 2018 - spiedigitallibrary.org
Predicting whether ductal carcinoma in situ (DCIS) identified at core biopsy contains occult
invasive disease is an import task since these “upstaged” cases will affect further treatment …

[HTML][HTML] Deep learning-based grading of ductal carcinoma in situ in breast histopathology images

SC Wetstein, N Stathonikos, JPW Pluim, YJ Heng… - Laboratory …, 2021 - Elsevier
Ductal carcinoma in situ (DCIS) is a non-invasive breast cancer that can progress into
invasive ductal carcinoma (IDC). Studies suggest DCIS is often overtreated since a …

A deep learning model for breast ductal carcinoma in situ classification in whole slide images

F Kanavati, S Ichihara, M Tsuneki - Virchows Archiv, 2022 - Springer
The pathological differential diagnosis between breast ductal carcinoma in situ (DCIS) and
invasive ductal carcinoma (IDC) is of pivotal importance for determining optimum cancer …

[HTML][HTML] Ultrasound deep learning radiomics and clinical machine learning models to predict low nuclear grade, ER, PR, and HER2 receptor status in pure ductal …

M Zhu, Y Kuang, Z Jiang, J Liu, H Zhang, H Zhao… - Gland …, 2024 - ncbi.nlm.nih.gov
Background Low nuclear grade ductal carcinoma in situ (DCIS) patients can adopt proactive
management strategies to avoid unnecessary surgical resection. Different personalized …

Interobserver variability in ductal carcinoma in situ of the breast

MR Van Bockstal, M Berlière… - American journal of …, 2020 - academic.oup.com
Objectives Since most patients with ductal carcinoma in situ (DCIS) of the breast are treated
upon diagnosis, evidence on its natural progression to invasive carcinoma is limited. It is …

Prospective analysis using a novel CNN algorithm to distinguish atypical ductal hyperplasia from ductal carcinoma in situ in breast

S Mutasa, P Chang, J Nemer, EP Van Sant, M Sun… - Clinical breast …, 2020 - Elsevier
Introduction We previously developed a convolutional neural networks (CNN)-based
algorithm to distinguish atypical ductal hyperplasia (ADH) from ductal carcinoma in situ …

Computational pathology to discriminate benign from malignant intraductal proliferations of the breast

F Dong, H Irshad, EY Oh, MF Lerwill, EF Brachtel… - PloS one, 2014 - journals.plos.org
The categorization of intraductal proliferative lesions of the breast based on routine light
microscopic examination of histopathologic sections is in many cases challenging, even for …

Sonography-based multimodal information platform for identifying the surgical pathology of ductal carcinoma in situ

H Wu, Y Jiang, H Tian, X Ye, C Cui, S Shi… - Computer Methods and …, 2024 - Elsevier
Background The risk of ductal carcinoma in situ (DCIS) identified by biopsy often increases
during surgery. Therefore, confirming the DCIS grade preoperatively is necessary for clinical …